Printer Friendly

MEDCO SIGNS BIDILTM MARKETING OPTION AGREEMENT WITH BOEHRINGER MANNHEIM PHARMACEUTICAL COMPANY

 LOS ANGELES, June 3 /PRNewswire/ -- Medco Research, Inc. (AMEX: MRE) announced today that it has signed an agreement with Boehringer Mannheim Pharmaceutical Corporation (BMPC), Rockville, Md. giving BMPC a 90-day option period ending Aug. 31, 1993 to negotiate and sign with Medco a marketing and sales agreement for BIDILTM in the U.S. and Canada. BMPC has paid Medco a non-refundable fee for the exclusive right to negotiate BIDILTM licensing terms with Medco during the 90-day period.
 Medco's BIDILTM product is a patented combination of hydralazine and isosorbide dinitrate (ISDN) for use in the treatment of congestive heart failure.
 A U.S. Veterans Administration-sponsored clinical trial (VHeFT-I) of a fixed combination of oral hydralazine and ISDN showed improved survival for congestive heart failure patients. Medco is proceeding with formulation studies of the BIDILTM product and plans to conduct bioequivalence clinical studies with the final product in approximately 45 patients. The data from the bioequivalence studies and from the completed VHeFT-I efficacy trial will form the basis of an NDA anticipated to be filed with FDA by the end of 1994.
 Medco Research, Inc. is a pharmaceutical company engaged in the acquisition, research and development of new prescription drugs for the diagnosis or treatment of certain cardiovascular diseases and cancer.
 -0- 5/3/93
 /CONTACT: Archie W. Prestayko, Ph.D. of Medco Research, Inc., 213-966-4148, or Fredric J. Spar of Kekst and Company, 212-593-2655/
 (MRE)


CO: Medco Research, Inc.; Boehringer Mannheim Pharmaceutical Corp. ST: California IN: MTC SU:

SM -- NY016 -- 4815 06/03/93 09:13 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 3, 1993
Words:256
Previous Article:AMES REPORTS MAY SALES
Next Article:COOK COUNTY (ILL.) $130 MILLION TAX ANTICIPATION NOTES RATED 'F-1+' BY FITCH -- FITCH FINANCIAL WIRE --
Topics:


Related Articles
RHONE-POULENC RORER AND BOEHRINGER MANNHEIM TO CO-DEVELOP THIRD GENERATION BISPHOSPHONATE.
BOEHRINGER MANNHEIM PHARMACEUTICALS CORPORATION TO MARKET NEW MEDCO HEART DRUG; AGENT COMBINES TWO VASODILATORS
ELAN AND BOEHRINGER MANNHEIM TO STRENGTHEN MARKETING PRESENCE IN JAPAN
ALTEON ANNOUNCES DIAGNOSTIC PARTNER FOR ITS A.G.E. TECHNOLOGY
BOEHRINGER MANNHEIM AND SMITHKLINE BEECHAM STRENGTHEN COLLABORATION TO MARKET CARVEDILOL WORLDWIDE
GENETICS INSTITUTE AND BOEHRINGER MANNHEIM EXPAND EPO PACT
GENZYME TRANSGENICS ANNOUNCES AGREEMENT WITH BOEHRINGER MANNHEIM
/C O R R E C T I O N -- CollaGenex Pharmaceuticals/(Correction Notice)
LXR Biotechnology Signs Collaboration With Boehringer Mannheim
Premier Announces Corporate Partnerships With Bayer Health Care Partners, Boehringer Mannheim Corporation, and 3M Health Care

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters